Dual purpose Prussian blue nanoparticles for cellular imaging and drug delivery: a new generation of T1-weighted MRI contrast and small molecule delivery agents

2010 ◽  
Vol 20 (25) ◽  
pp. 5251 ◽  
Author(s):  
Mohammadreza Shokouhimehr ◽  
Eric S. Soehnlen ◽  
Jihua Hao ◽  
Mark Griswold ◽  
Chris Flask ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Prussian Blue ◽  
Small Molecule ◽  
Cellular Imaging ◽  
Dual Purpose ◽  
Mri Contrast ◽  
Prussian Blue Nanoparticles ◽  
New Generation

Zwitterion-Functionalized Hollow Mesoporous Prussian Blue Nanoparticles for Targeted and Synergetic Chemo-Photothermal Treatment of Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Huiyuan Bai ◽  
Quanhao Sun ◽  
Fei Kong ◽  
Hai-Jiao Dong ◽  
Ming Ma ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Acute Myeloid Leukemia ◽  
Prussian Blue ◽  
Myeloid Leukemia ◽  
Drug Delivery Systems ◽  
High Efficacy ◽  
Tumor Treatment ◽  
Prussian Blue Nanoparticles ◽  
Photothermal Treatment ◽  
Acute Myeloid

Multifunctional drug delivery systems combining two or more therapies have broad prospects for high efficacy tumor treatment. Herein, we designed a novel hollow mesoporous Prussian blue nanoparticles (HMPBs)-based platform for...

scholarly journals Facile synthesis of Prussian blue nanoparticles as pH-responsive drug carriers for combined photothermal-chemo treatment of cancer

RSC Advances ◽  
2017 ◽  
Vol 7 (1) ◽  
pp. 248-255 ◽  
Author(s):  
Huajian Chen ◽  
Yan Ma ◽  
Xianwen Wang ◽  
Xiaoyi Wu ◽  
Zhengbao Zha
Keyword(s):  
Drug Delivery ◽  
Prussian Blue ◽  
Cancer Cells ◽  
Drug Carriers ◽  
High Efficacy ◽  
Ph Responsive ◽  
Facile Synthesis ◽  
Drug Delivery Vehicles ◽  
Prussian Blue Nanoparticles ◽  
Delivery Vehicles

Multifunctional PEGylated PB-DOX NPs with a lipid-PEG shell were developed as a gram-scale manner and used as novel pH-responsive drug delivery vehicles for combined photothermal-chemo treatment of cancer cells with high efficacy.

scholarly journals Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Krisztián Szigeti ◽  
Nikolett Hegedűs ◽  
Kitti Rácz ◽  
Ildikó Horváth ◽  
Dániel S. Veres ◽  
...  
Keyword(s):  
Prussian Blue ◽  
Contrast Material ◽  
Mri Contrast Agent ◽  
Mri Contrast ◽  
Potential Measurement ◽  
Force Microscopy ◽  
Prussian Blue Nanoparticles ◽  
Volume Of Interest ◽  
Diagnostic Applications

Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

Biocompatible Prussian blue nanoparticles: Preparation, stability, cytotoxicity, and potential use as an MRI contrast agent

2010 ◽  
Vol 13 (1) ◽  
pp. 58-61 ◽  
Author(s):  
Mohammadreza Shokouhimehr ◽  
Eric S. Soehnlen ◽  
Anatoly Khitrin ◽  
Soumitra Basu ◽  
Songping D. Huang
Keyword(s):  
Contrast Agent ◽  
Prussian Blue ◽  
Mri Contrast Agent ◽  
Mri Contrast ◽  
Prussian Blue Nanoparticles ◽  
Potential Use

Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications

2020 ◽  
Vol 21 (11) ◽  
pp. 885-901
Author(s):  
Shubham Thakur ◽  
Amrinder Singh ◽  
Ritika Sharma ◽  
Rohan Aurora ◽  
Subheet Kumar Jain
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Toxicity Testing ◽  
Pharmaceutical Formulations ◽  
Delivery Systems ◽  
Surface Active Agents ◽  
Regulatory Status ◽  
Different Temperatures ◽  
High Production Cost ◽  
New Generation

Background: Surfactants are an important category of additives that are used widely in most of the formulations as solubilizers, stabilizers, and emulsifiers. Current drug delivery systems comprise of numerous synthetic surfactants (such as Cremophor EL, polysorbate 80, Transcutol-P), which are associated with several side effects though used in many formulations. Therefore, to attenuate the problems associated with conventional surfactants, a new generation of surface-active agents is obtained from the metabolites of fungi, yeast, and bacteria, which are termed as biosurfactants. Objectives: In this article, we critically analyze the different types of biosurfactants, their origin along with their chemical and physical properties, advantages, drawbacks, regulatory status, and detailed pharmaceutical applications. Methods: 243 papers were reviewed and included in this review. Results: Briefly, Biosurfactants are classified as glycolipids, rhamnolipids, sophorolipids, trehalolipids, surfactin, lipopeptides & lipoproteins, lichenysin, fatty acids, phospholipids, and polymeric biosurfactants. These are amphiphilic biomolecules with lipophilic and hydrophilic ends and are used as drug delivery vehicles (foaming, solubilizer, detergent, and emulsifier) in the pharmaceutical industry. Despite additives, they have some biological activity as well (anti-cancer, anti-viral, anti-microbial, P-gp inhibition, etc.). These biomolecules possess better safety profiles and are biocompatible, biodegradable, and specific at different temperatures. Conclusion: Biosurfactants exhibit good biomedicine and additive properties that can be used in developing novel drug delivery systems. However, more research should be driven due to the lack of comprehensive toxicity testing and high production cost which limits their use.

scholarly journals 601 Development of improved small molecule STING agonists suitable for systemic administration

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A636-A636
Author(s):  
Maciej Rogacki ◽  
Stefan Chmielewski ◽  
Magdalena Zawadzka ◽  
Jolanta Mazurek ◽  
Katarzyna Wnuk-Lipińska ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Small Molecule ◽  
Immune Cells ◽  
Systemic Administration ◽  
Cytokine Release ◽  
Major Player ◽  
Human Immune ◽  
New Generation ◽  
Dose Dependent ◽  
Complete Tumor

BackgroundStimulator of Interferon Genes (STING) is a major player in the activation of robust innate immune response leading to initiation and enhancement of tumor-specific adaptive immunity. Several clinical and pre-clinical programs have shown that activation of the STING pathway triggers immune-mediated antitumor response. Although vast majority of programs focus on development of analogues of the endogenous STING ligands, their chemical nature and stability often limit their use to local administration. Herein, we present recent results from the development of our selective non-nucleotide, non-macrocyclic, small molecule direct STING agonists, suitable for systemic administration, characterized by improved activity in human immune cells.MethodsBinding to recombinant STING protein was examined using FTS, MST, FP and crystallography studies. Phenotypic screen was performed in THP-1 Dual reporter cells. Mouse bone marrow-derived dendritic cells (BMDC) were obtained from C57BL/6 mice and differentiated with mIL-4 and mGM-CSF. STING agonists were administered into BALB/c mice and cytokine release was measured in plasma. Additionally, mice were inoculated with CT26 murine colon carcinoma or EMT6 murine breast carcinoma cells and the compound was administered, followed by the regular tumor growth and body weight monitoring.ResultsRyvu’s small-molecule agonists demonstrate strong binding affinity to recombinant STING proteins across all tested species. The compounds bind to all human STING protein variants and trigger pro-inflammatory cytokine release from human immune cells regardless of the STING haplotype. Moreover, new generation of developed agonists show significantly improved binding to human protein as well as in vitro activity on human cells. Systemic, intravenous in vivo administration leads to a dose-dependent upregulation of STING-dependent pro-inflammatory cytokines, which results in a dose-dependent antitumor efficacy observed in CT26 and EMT6 mouse cancer models, leading to complete tumor remissions in all treated animals. Furthermore, observed efficacy is accompanied by development of a lasting immunological response demonstrated by lack of tumor engraftment or a delayed tumor growth in cured animals challenged with repeated inoculation of cancer cells.ConclusionsNew generation Ryvu’s STING agonists are strong and selective activators of STING-dependent signaling in both mouse and human immune cells promoting anti-tumor immunity. Treatment with Ryvu’s small-molecule STING agonists leads to engagement of the immune system which results in a complete tumor remission and development of immunological memory of the cancer antigens. The compounds show good selectivity and ADME properties enabling development for systemic administration. In addition developed compounds maintain small functional handles amenable to linker attachment making the series suitable for versatile development as single agents, for combinations with immunotherapies or as targeted agents.

scholarly journals Organotrialkoxysilane-Functionalized Prussian Blue Nanoparticles-Mediated Fluorescence Sensing of Arsenic(III)

Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1145
Author(s):  
Prem. C. Pandey ◽  
Shubhangi Shukla ◽  
Roger J. Narayan
Keyword(s):  
Prussian Blue ◽  
Chemical Reduction ◽  
Low Cost ◽  
Three Dimensional ◽  
Heterogeneous Systems ◽  
Lattice Points ◽  
Radiative Energy ◽  
Fluorescence Sensing ◽  
Emission Signal ◽  
Prussian Blue Nanoparticles

Prussian blue nanoparticles (PBN) exhibit selective fluorescence quenching behavior with heavy metal ions; in addition, they possess characteristic oxidant properties both for liquid–liquid and liquid–solid interface catalysis. Here, we propose to study the detection and efficient removal of toxic arsenic(III) species by materializing these dual functions of PBN. A sophisticated PBN-sensitized fluorometric switching system for dosage-dependent detection of As3+ along with PBN-integrated SiO2 platforms as a column adsorbent for biphasic oxidation and elimination of As3+ have been developed. Colloidal PBN were obtained by a facile two-step process involving chemical reduction in the presence of 2-(3,4-epoxycyclohexyl)ethyl trimethoxysilane (EETMSi) and cyclohexanone as reducing agents, while heterogeneous systems were formulated via EETMSi, which triggered in situ growth of PBN inside the three-dimensional framework of silica gel and silica nanoparticles (SiO2). PBN-induced quenching of the emission signal was recorded with an As3+ concentration (0.05–1.6 ppm)-dependent fluorometric titration system, owing to the potential excitation window of PBN (at 480–500 nm), which ultimately restricts the radiative energy transfer. The detection limit for this arrangement is estimated around 0.025 ppm. Furthermore, the mesoporous and macroporous PBN-integrated SiO2 arrangements might act as stationary phase in chromatographic studies to significantly remove As3+. Besides physisorption, significant electron exchange between Fe3+/Fe2+ lattice points and As3+ ions enable complete conversion to less toxic As5+ ions with the repeated influx of mobile phase. PBN-integrated SiO2 matrices were successfully restored after segregating the target ions. This study indicates that PBN and PBN-integrated SiO2 platforms may enable straightforward and low-cost removal of arsenic from contaminated water.

Sign in / Sign up

Export Citation Format

Share Document